NCT01158417.

Trial name or title	Acronym: —
Methods	Type of trial: efficacy trial Allocation: randomised Intervention model: parallel assignment Masking: single‐blind (participant) Primary purpose: treatment
Participants	Condition: type 2 diabetes mellitus, obesity, and Insulin resistance Enrolment: estimated 102 Inclusion criteria 20 years of age or older Healthy obese patients with BMI > 30 Type 2 diabetic patients with BMI > 30 Patients with good peripheral vein Patients on statins, ACE inhibitors, and thiazolidinediones will be allowed as long as they are on stable doses of these compounds and the dosage is not changed during the course of the study Exclusion criteria Patients on any anti‐oxidant medication Patients on non‐steroidal anti‐inflammatory drugs Patients on any agent with significant anti‐oxidant properties History of drug or alcohol abuse Any life‐threatening disease Allergy to peanuts, grapes, wine, mulberries Pregnant women Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass surgery, or coronary angioplasty) in previous 4 weeks Patients on anticoagulants
Interventions	Intervention(s): resveratrol (40 mg oral 3 times a day or 500 mg oral once daily) Comparator(s): placebo tablets
Outcomes	Primary outcome(s): NF‐Kb Secondary outcome(s): GLP‐1 Other outcome(s): —
Starting date	Trial start date: December 2008 Trial completion date: August 2014 (estimated)
Contact information	Responsible party/principal investigator: Paresh Dandona, MD, Kaleida Health
Study identifier	Trial identifier:NCT01158417
Official title	Effect of resveratrol on insulin resistance and inflammatory mediators in obese and type 2 diabetic subjects
Stated purpose of study	Quote: "The main objective of this study is to investigate the effect of resveratrol on inflammatory mediators and insulin resistance at the cellular and molecular level in obese non diabetic and type 2 diabetic subjects in vivo"
Notes